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management  approach  of  each  patient  and  to  address  prognosis  issues.
In  this  manuscript,  we  will  discuss  the  impact  of  the  most  recent  staging  categories
(7th  TNM  staging)  on  the  management  of  non-small  cell  lung  cancer.
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he  7th  edition  of  TNM  Staging  in  lung  cancer  is  the
rst classiﬁcation  to  be  based  upon  global  data.  The
evisions are  entirely  based  on  the  recommenda-
ions of  the  International  Association  for  the  Study
ung Cancer  (IASLC)  Staging  Project,  derived  from
he IASLC  International  Database  for  Lung  Cancer,
nd were  accepted  without  change  by  the  Inter-
ational  Union  for  Cancer  Control  (UICC)  and  the
merican  Joint  Commission  on  Cancer  (AJCC).
Data were  collected  from  46  databases  in  more
han 20  countries  around  the  world.  81,495  were
vailable  for  ﬁnal  analysis,  68,463  cases  of  Non
mall Cell  Lung  Cancer  (NSCLC)  and  13,032  cases  of
mall-cell lung  cancer  (SCLC).  Data  on  cases  treated
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y  all  modalities  of  care  have  been  intensively  val-
dated internally  and  externally  [1].
he changes in the 7th edition
a. Size  cut  points  3  cm  is  the  cut  point  that  sep-
arated T1  and  T2  tumors  was  changed  with
introduction of  new  cut  point  at  2,  5,  and  7 cm.
T1 tumors  are  now  subdivided  into  T1a  and  T1b
around  the  2  cm  cut  point.  T2  tumors  have  been
subdivided  into  T2a  and  T2b  around  the  5  cm  cut
point, and  tumors  >7  cm  are  now  classiﬁed  as  T3
[2].
. Reclassiﬁcation  of  cases  with  additional  tumor
nodules  as  follows:  T3  for  tumors  with  additional
nodules in  the  same  lobe  as  the  primary  tumor.
T4 when  nodules  in  ipsilateral  lobes.  M1a  for
those  in  the  opposite  lung  [2,3].
c.  Cases  associated  with  pleural  or  pericardial  nod-
ules/effusions  have  been  reclassiﬁed  from  T4  to
M1a [3].
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d.  M1  disease  due  to  distant  metastases  has  been
reclassiﬁed  as  M1b  [3].
e. The  utility  of  the  TNM  classiﬁcation  in  small-
cell lung  cancer  treated  by  all  modalities  of  care
[4,5].
f. The  validity  of  TNM  in  Carcinoid  tumors  [6].
g. A  new  IASLC  nodal  chart,  with  precise  deﬁni-
tions. With  introduction  of  the  concept  of  nodal
‘‘zones’’  [7].
h.  Introduction  of  a  precise  deﬁnition  of  ‘‘visceral
pleural invasion,’’  with  the  use  of  elastic  stains
[8].
These changes result in following stage
grouping: [1]
a.  Down-staged  T2a  (>3  to  ≤5  cm)  N1  M0  from  stage
IIB to  IIA.
. Up-staged  T2b  (>5  to  ≤7  cm)  N0  M0  tumors  from
stage  IB  to  IIA.
c.  Up-staged  T3  (>7  cm)  N0  M0  from  IB  to  IIB  and
T3 N1  M0  from  IIB  to  IIIA.
. Down-staged  T3  (additional  tumor  nodules  in
same lobe  of  the  primary),  N0  to  stage  IIB  and
N1 or  N2  to  stage  IIIA  from  IIIB.
e. Down staged  T4  (additional  tumor  nodules  in
other ipsilateral  lobes,  to  stage  IIIA  if  N0  or  N1
and N2  to  stage  IIIB  from  stage  IV;  if  N2  or  N3.
f. Down  staged  T4  (other  features)  to  stage  IIIA
from stage  IIIB  with  N0  or  N1.
g. Up-staged  tumors  associated  with  pleural  or
pericardial  nodules/effusions  to  M1a  instead  of
T4. i.e.  from  IIIB  to  stage  IV.
Some of  these  changes  to  stage  groupings  will
have consequences  for  established  treatment  algo-
rithms. The  moving  of  the  node  negative  T2b,
T3 from  stage  IB  into  stage  IIA  and  stage  IIB,
respectively, will  raise  the  question  of  adjuvant
chemotherapy after  complete  resection.  Although
there  is  still  doubt  as  to  the  value  of  adjuvant
chemotherapy  after  complete  resection  for  node
negative  cases  in  stage  IB  [9,10].  At  least  two  large
trials have  shown  a  beneﬁt  for  node-positive  cases
in stages  II  and  IIIA  [11,12].  The  question  as  to
whether  these  larger  node  negative  tumors  bene-
ﬁt from  adjuvant  therapy  will  only  be  resolved  by
large, prospective,  randomized  trials.
General  agreement  that,  the  size  of  tumor  had
major role  in  chemotherapy  for  even  early  stage.
Tumors  less  than  3  cm  should  have  no  chemother-
apy. For  tumors  from  3  to  5  cm,  chemotherapy  is
optional.  For  tumors  of  5—7  cm,  giving  chemother-
apy is  preferred,  and  for  tumors  above  7  cm  they
t
n
l
fA.  Bamousa,  K.  AlKattan
re  considered  as  T3  and  chemotherapy  is  indicated
1—13].
The  reassignment  of  cases  with  additional  nod-
les in  an  ipsilateral,  nonprimary  tumor  bearing
obe into  a  T4  descriptor  rather  than  an  M1  descrip-
or and  the  relocation  of  T4  N0  M0  and  T4  N1  M0
ases into  stage  IIIA  will  also  lead  to  questions  as  to
he appropriate  treatment  algorithm.  Multimodal-
ty treatment  models,  some  including  surgery,  will
o doubt  evolve  as  a  result  of  appropriate  trials.
Patient with  a single  M1  lesion  in  the  lung  raises
he question  of  whether  this  is  an  M1  disease  or  mul-
iple primaries  [14—18].  A  spiculated  or  lobulated
esion often  indicates  a  primary  tumor,  whereas
 smooth  border  is  more  often  seen  in  hemato-
eneic metastases.  These  patients  can  be  treated
s two  primaries  tumors  with  surgical  approach,  4D
igh-dose radiotherapy  or  as  disseminated  disease
stage IV)  by  systemic  treatment.[19,20]  A  multidis-
iplinary team  management  is  recommended  with
trong consideration  of  curative  approach  as  two
rimaries.
The IASLC  propose  Lymph  Node  Map  to  achieve
niformity and  to  promote  future  analyses  of  a
lanned  prospective  international  database  [21].
It has  been  found  that  lymphatic  drainage  of
he superior  mediastinum  predominantly  occurs  to
he right  paratracheal  area  and  extends  past  the
idline  of  the  trachea,  the  boundary  between  the
ight- and  left-sided  levels  2  and  4  lymph  nodes
as been  reset  to  the  left  lateral  wall  of  the  tra-
hea. Level  3 lymph  nodes  as  nodes  overlying  the
idline  of  the  trachea  in  the  Naruke  map  has
een eliminated  because  these  nodes  are  not  reli-
bly distinguishable  from  levels  2  and  4  and  are
enerally  removed  en-bloc  with  level  4  during  sys-
ematic nodal  dissection.  The  sub  carinal  group
f lymph  nodes  level  7 deﬁned  as  lymph  node
ocated below  carina  and  above  the  upper  border
f lower  lobe  bronchus  on  left;  above  border  of
ronchus  intermedius  on  the  right  side.  The  zone
oncept  is  proposed  for  future  survival  analyses,  not
or current  standard  nomenclature.  This  well  clear
onfusion  with  large  nodal  masses  that  transgress
ndividual nodal  stations.
Areas  of  continuing  controversy  regarding  the
elationship  between  lymph  nodes  metastases  and
verall survival  include:  intranodal  versus  extran-
dal disease  [22];  single  versus  multiple  (either  N1
r N2)  lymph  node  station  disease  [23—30];  the  spe-
iﬁc sites  of  lymph  node  metastases  in  relationship
o the  location  of  the  primary  tumor  [24,26,29];
he signiﬁcance  of  skip  metastases  [23];  and  the
eed for  systematic  lymph  node  dissection  versus  a
ess extensive  lymph  node  sampling  [31]  especially
or tumors  less  than  2  cm  in  size  [32].  Analyses  of
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he  IASLC  database  suggested  that  left  upper  lobe
umors with  skip  metastases  in  the  AP  zone  (lev-
ls 5  and  6)  were  associated  with  a  more  favorable
rognosis than  other  N2  subsets.
In addition,  analyses  of  the  potential  impact
f the  number  of  involved  lymph  node  zones  on
urvival  found  three  groups  to  have  signiﬁcantly
ifferent survival  rates:  patients  who  had  N1  sin-
le zone  disease,  those  who  had  either  multiple  N1
r single  N2  zone  metastases,  and  those  who  had
ultiple  N2  lymph  node  zones  involved.  Multiple
nvolvement N1  disease  needs  chemotherapy  while
ingle station  of  N1  disease  dose  not  and  N2  disease
hat present  as  single  disease  has  better  survival
han multiple  although  this  did  not  reach  statis-
ically  signiﬁcant  and  wasn’t  included  in  7th  TNM
taging [22].
In  summary  the  new  staging  system  was  devel-
ped based  on  large  global  data  that  resulted
n changes  in  some  of  the  old  stage  grouping
nd development  of  new  stage  classiﬁcation.  The
mpact on  the  management  of  patients  will  require
urther  evaluation  and  research.
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